Life 4 Liam
Nizubaglustat
Azafaros’ oral medicine in the global Phase 3 NAVIGATE study. A brain-penetrant substrate-reduction approach. It is not miglustat, and it is not approved.
How it works
Nizubaglustat is taken by mouth. Like other substrate-reduction approaches, the aim is to slow how many lipids the cell makes, so less material piles up behind the NPC traffic jam. Azafaros describes it as brain-penetrant, meaning the medicine is designed to reach the nervous system.
NAVIGATE is a global Phase 3 study in NPC. Families should treat trial news as news about a study, not as a new standard of care.
Who it is for
People who may be eligible for the NAVIGATE trial. An NPC specialist is the person who knows whether a child or adult can be considered. It is not an approved medicine.
What it does not do
It does not restore NPC1. It is not miglustat, and it is not the companion medicine paired with Miplyffa. A Phase 3 study is not an approval.
What this treatment does
Four short pictures of the idea. Play through, or tap a step. This is a teaching picture, not a medical simulation.
Step 1 of 4 · The problem
Lipids keep arriving at a blocked lysosome
The cell cannot clear cholesterol normally. New lipid material keeps being made.
Official information
Educational only. Ask an NPC specialist what is right for a specific child or adult. Official sites and FDA pages are the source of prescribing information.